{"id":"W2769972801","doi":"10.1158/1078-0432.ccr-17-1590","title":"A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"National Cancer Institute; Ovarian Cancer Research Fund","keywords":"Veliparib; Topotecan; Medicine; PARP inhibitor; Internal medicine; Neutropenia; Olaparib; Oncology; Febrile neutropenia; Gastroenterology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Surgery; Pharmacology; Clinical trial; Chemotherapy; Poly ADP ribose polymerase; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001959729,0.001819714,0.002461726,0.0004393196,0.0004908342,0.001011055,0.001042287,0.001191776,0.00276545],"category_scores_gemma":[0.001305293,0.0008516659,0.001128219,0.0005080742,0.001176386,0.000769356,0.0003921507,0.004043372,0.0006466121],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001107417,"about_ca_system_score_gemma":0.002153616,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00073282,"about_ca_topic_score_gemma":0.001419117,"domain_scores_codex":[0.9993168,0.0003689897,0.0000404664,0.00009494041,0.00006037105,0.0001183325],"domain_scores_gemma":[0.9987383,0.0002654197,0.0002402901,0.00009731325,0.0000590237,0.0005995808],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8107709,0.08028834,0.006473655,0.0006956036,0.001079867,0.000431962,0.0002612547,0.003396839,0.03366219,0.0002887301,0.002908157,0.05974248],"study_design_scores_gemma":[0.6254877,0.3643074,0.004792739,0.00002274453,0.0002418881,0.0002180983,0.00003272943,0.00135149,0.002482905,0.0001067973,0.0009380926,0.00001734817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949704,0.001100779,0.000378822,0.0003208157,0.0001116317,0.001627441,0.0003840775,0.00004782048,0.001058179],"genre_scores_gemma":[0.9925094,0.0008141517,0.001357293,0.0005046115,0.0002419821,0.002160666,0.001107232,0.00001495974,0.001289818],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00276545,"threshold_uncertainty_score":0.01036417,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2537814787584608,"score_gpt":0.5781930088015869,"score_spread":0.3244115300431261,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}